| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_df05e1a249c7498d76ba1afb3e82ff97 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-4709
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-28 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6896
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D213-74
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-444
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-444
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4375
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-02 |
| filingDate |
2010-10-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_65d44dee17a141a1578ebbad42275fe1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_470225b3f1ed813fe8f99b7b935546f3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_529d0eeb0f4e28b48bb90ca4ff99429c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_855863b91dd664dc1038d0f7947f73df |
| publicationDate |
2022-08-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
BR-112012008843-B1 |
| titleOfInvention |
COMPOUND, PHARMACEUTICAL COMPOSITION, USE OF COMPOUND AND MIXTURE |
| abstract |
COMPOUND, PHARMACEUTICAL COMPOSITION, USE OF COMPOUND AND MIXTURE. The present invention pertains to 2,6-diaminopyridine compounds which can be used in the treatment of a group of disorders and abnormalities associated with amyloid protein and diseases or conditions associated with amyloid equivalent proteins. The compounds of the present invention can also be used in the treatment of eye diseases associated with abnormalities/pathological changes in the tissues of the visual system. |
| priorityDate |
2009-10-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |